Use of them does not imply any affiliation with or endorsement by them.
Prieto-Granada CN, Wiesner T, Messina JL et al
Most GLP-1 users experience mild nausea, constipation, or reduced appetite intensity during the first 2-4 weeks, which typically resolves as your body adapts
KPV reduces inflammation by inhibiting NF-kB signaling, one of the most studied inflammatory pathways in medicine, and is absorbed through a dedicated intestinal transporter called PepT1
If using a commercial product, verify the stated concentration and confirm the product has been stored properly even a 2% formulation delivers zero benefit if peptide degradation has reduced active content to 0.5% or less
Humalog and NovoLog havent been directly compared in large clinical studies